Skip to Content

Advantis Corp ADVT

Morningstar Rating
$0.00 0.00 (0.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ADVT is trading at a 373% premium.
Price
$0.00
Fair Value
$8.47
Uncertainty
Extreme
1-Star Price
$8.72
5-Star Price
$1.89
Economic Moat
Svcq
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ADVT is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.00
Day Range
$0.000.00
52-Week Range
$0.000.00
Bid/Ask
/
Market Cap
$978.47
Volume/Avg
139,829 / 95,338

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Advantis Corp is a development stage company. It is pursuing business opportunities to the development of pharmaceutical grade CBD extractions, concentrates and medicines in Nevada, California, and Washington. The company is also establishing partnerships with businesses that develop and sell proprietary consumer products and services. It is developing a product line for the consumer, music, and entertainment sectors.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Total Number of Employees
12
Website

Valuation

Metric
ADVT
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
ADVT
Quick Ratio
0.14
Current Ratio
0.36
Interest Coverage
Quick Ratio
No chart available

Profitability

Metric
ADVT
Return on Assets (Normalized)
−21.41%
Return on Equity (Normalized)
−60.50%
Return on Invested Capital (Normalized)
−46.57%
Return on Assets
No chart available
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - Specialty & Generic Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Zoetis Inc Class A
ZTS
JkwcscqtyPtzv$82.1 Bil
Merck KGaA ADR
MKKGY
VzxgnwsyzKpflqfv$75.2 Bil
Haleon PLC ADR
HLN
GtvfzyjjSkl$41.4 Bil
Viatris Inc
VTRS
SwzpnzbwDptwr$14.4 Bil
Dr Reddy's Laboratories Ltd ADR
RDY
GhsdgxlsWkkls$13.7 Bil
Catalent Inc
CTLT
TpmmbjgHpbvdq$10.6 Bil
Perrigo Co PLC
PRGO
CsgnwlvtlRbgmj$3.8 Bil
Prestige Consumer Healthcare Inc
PBH
YwzymvkbJvffdl$3.5 Bil
Curaleaf Holdings Inc
CURLF
NyvvjxzzdTthjj$3.0 Bil
Green Thumb Industries Inc
GTBIF
VwqbcywhvQpc$2.7 Bil

Sponsor Center